GHK-Cu and Pregabalin Interaction: What Patients and Clinicians Need to Know

What Are GHK-Cu and Pregabalin, and Why Does the Interaction Question Arise?

GHK-Cu is a naturally occurring copper-binding tripeptide (glycine-histidine-lysine complexed with Cu2+) found in human plasma, saliva, and urine. Pregabalin is an alpha-2-delta calcium channel ligand approved by the FDA for neuropathic pain, fibromyalgia, partial-onset seizures, and generalized anxiety disorder. Patients prescribed pregabalin for neuropathic pain or fibromyalgia often seek adjunct peptide therapies for tissue repair, inflammation, or skin benefits, creating the clinical scenario where co-administration questions arise.

GHK-Cu: Mechanism and Regulatory Status

GHK-Cu was first isolated from human plasma albumin by Pickart in 1973. In vitro and rodent data show it stimulates collagen and glycosaminoglycan synthesis, activates matrix metalloproteinase remodeling pathways, and upregulates antioxidant enzymes including superoxide dismutase and catalase [1]. A 2012 review by Pickart and Margolina in Biomolecules catalogued over 30 genes modulated by GHK-Cu in human fibroblast cultures, including upregulation of VEGF and downregulation of inflammatory cytokines [2].

GHK-Cu carries no FDA-approved New Drug Application. It is dispensed in the United States exclusively through 503A compounding pharmacies, meaning batch-to-batch purity, carrier excipients, and sterility standards vary. The FDA's compounding guidance under 21 U.S.C. 503A does not require the same bioequivalence or interaction testing required of approved drugs [3].

Pregabalin: Mechanism and FDA Label Highlights

Pregabalin (Lyrica, Pfizer) binds the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn, reducing glutamate, norepinephrine, and substance P release [4]. The FDA label (NDA 021446) lists the following key pharmacokinetic parameters: oral bioavailability greater than 90%, linear pharmacokinetics up to 600 mg/day, renal elimination as unchanged drug (greater than 98%), and no meaningful hepatic CYP metabolism [4].

The Schedule V classification reflects abuse and dependence risk. The FDA label states that "pregabalin produced increases in maximum drug liking on a Visual Analog Scale... Similar to diazepam" in recreational drug users [4]. This CNS and euphoric liability is the reason any co-administered agent with potential CNS activity demands careful evaluation.

Pharmacokinetic Interaction Analysis: CYP, P-gp, and Renal Pathways

The formal DDI risk between GHK-Cu and pregabalin is low at the pharmacokinetic level, but the reasoning matters for clinical practice.

Why CYP450 Is Not Relevant Here

Pregabalin does not undergo hepatic cytochrome P450 metabolism. The FDA label explicitly notes it is "not metabolized to an appreciable extent" and does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 [4]. GHK-Cu, as a tripeptide, is hydrolyzed in plasma and tissue to its constituent amino acids (glycine, histidine, lysine) and free Cu2+ ion. Glycine, histidine, and lysine are not known CYP substrates or inhibitors [5]. Consequently, neither drug alters hepatic CYP-mediated clearance of the other.

P-glycoprotein and Transporter Interactions

Pregabalin is not a substrate, inhibitor, or inducer of P-glycoprotein (P-gp) or organic anion transporters [4]. Tripeptides of the GHK class are too small (molecular weight approximately 340 Da for GHK free acid) and too rapidly hydrolyzed to engage P-gp efflux transporters in any clinically meaningful way [5]. No published transporter interaction data exist for GHK-Cu specifically.

Renal Clearance and Copper Load

Pregabalin is eliminated renally as unchanged drug; dose reduction is required when creatinine clearance falls below 60 mL/min [4]. GHK-Cu delivers a small copper load (microgram-range in typical compounded doses of 1-5 mg/mL applied topically or injected subcutaneously). Copper excretion is primarily biliary, not renal. At therapeutic doses, the copper increment is unlikely to affect tubular secretion of pregabalin. No published renal interaction data exist for this combination.

Pharmacodynamic Interaction Analysis: CNS, BDNF, and Copper-Enzyme Pathways

Pharmacodynamic interactions are harder to quantify and represent the main area of clinical uncertainty for this pair.

Pregabalin's CNS Depression Profile

Pregabalin produces dose-dependent dizziness, somnolence, and cognitive slowing. In the pooled neuropathic pain trials submitted to the FDA, dizziness occurred in 29% and somnolence in 22% of pregabalin-treated patients versus 8% and 7% of placebo, respectively [4]. Any co-administered substance with CNS-modulating activity could amplify these effects.

GHK-Cu and Central Nervous System Biology

GHK-Cu's CNS biology is incompletely characterized. A 2018 analysis of GHK's gene-expression signature in the Broad Institute Connectivity Map database, published in Aging (Albany NY), found overlap with gene sets associated with neuroprotection and BDNF upregulation [6]. BDNF potentiates GABAergic signaling in the hippocampus, and pregabalin's alpha-2-delta mechanism also modulates inhibitory tone. Whether this overlap produces additive sedation in humans is unknown; no human trial has tested the combination.

Copper-Dependent Enzyme Considerations

Free copper ion, released from GHK-Cu after hydrolysis, is a cofactor for dopamine beta-hydroxylase, cytochrome c oxidase, and superoxide dismutase [7]. Dopamine beta-hydroxylase converts dopamine to norepinephrine; reduced copper bioavailability theoretically could shift catecholamine balance. Pregabalin reduces norepinephrine release at the synapse. A theoretical convergence exists, but the copper doses delivered by compounded GHK-Cu formulations (typically 2-10 micrograms per injection) are orders of magnitude below the levels that affect systemic copper-enzyme activity [7].

Severity Classification and Clinical DDI Rating

Using the standard DDI classification framework applied in hospital pharmacy (contraindicated / major / moderate / minor / no interaction), this combination fits the "minor-to-unknown" category at present, driven by:

1. No pharmacokinetic mechanism for interaction (neither CYP nor P-gp).
2. Theoretical but unquantified pharmacodynamic overlap via BDNF and norepinephrine pathways.
3. Absence of any human DDI trial or spontaneous adverse-event report in the FDA Adverse Event Reporting System (FAERS) database for this pair as of the date of this review.

The Lexicomp and Micromedex DDI databases do not list GHK-Cu as an indexed drug, reflecting its non-approved status. Clinicians cannot rely on automated pharmacy checking systems to flag this pair.

What FAERS Data Show

A targeted FAERS query (OpenFDA API, drugs endpoint) for GHK-Cu as a suspect or concomitant drug returns zero case reports [8]. This reflects low reporting and low usage volume, not demonstrated safety. Absence of reports in FAERS does not establish safety for a non-approved compounded peptide.

Monitoring Parameters When Co-Prescribing

Clinical Signs to Track

Patients co-using GHK-Cu and pregabalin should be evaluated at each visit for:

• Excess somnolence or sedation beyond what pregabalin alone produces at baseline
• Dizziness, ataxia, or balance disturbance
• Cognitive slowing or memory complaints new to the combination period
• Skin or injection-site reactions (specific to subcutaneous GHK-Cu)

Pregabalin does not have a standard therapeutic drug monitoring serum assay used in outpatient practice, so monitoring is clinical rather than laboratory-based for most patients [4].

Laboratory Monitoring

Serum copper and ceruloplasmin measurement is warranted if a patient uses high-dose or prolonged systemic GHK-Cu, because supraphysiologic copper loading can cause hepatotoxicity and neurological symptoms. The normal adult serum copper range is 70-140 micrograms/dL [9]. Topical GHK-Cu formulations are unlikely to produce systemic copper elevation, but subcutaneous or intravenous compounded preparations carry a higher risk of inadvertent copper accumulation, particularly in patients with Wilson disease or cholestatic liver disease.

Renal function (creatinine, eGFR) should be monitored per standard pregabalin prescribing practice, since pregabalin dose must be adjusted for renal impairment [4].

Patient Counseling Points

What to Tell Patients Using Both Agents

Patients should understand the following before combining GHK-Cu with pregabalin:

• No human trial has confirmed this combination is safe or effective for any indication.
• Pregabalin carries real sedation and dependency risk; adding any agent without controlled data is a decision that requires physician oversight.
• Compounded GHK-Cu is not FDA-approved. Purity, sterility, and dose accuracy depend entirely on the compounding pharmacy's compliance with USP 795/797 standards.
• Patients should report any new dizziness, confusion, or unusual fatigue within the first two weeks of starting GHK-Cu while on pregabalin.
• Alcohol and other CNS depressants (benzodiazepines, opioids, muscle relaxants) must not be added to pregabalin without physician guidance; GHK-Cu does not fall into this high-risk CNS depressant class but its CNS profile in humans is not fully mapped.

Abuse Potential Consideration

Pregabalin's Schedule V status reflects documented misuse. The FDA label notes that "evaluate patients for history of drug abuse and observe for signs of pregabalin misuse or abuse" [4]. GHK-Cu has no known abuse potential, but clinicians treating patients with pregabalin misuse history should be cautious about any self-sourced injectable peptide use, as this behavior pattern may signal broader risk of unsupervised self-medication.

Special Populations

Renal Impairment

Renal impairment changes pregabalin pharmacokinetics substantially. Patients with creatinine clearance <30 mL/min require significant pregabalin dose reduction, and hemodialysis patients require supplemental dosing after each session [4]. GHK-Cu interaction risk does not change in renal impairment based on available data, but copper accumulation risk may increase in patients with impaired copper excretion pathways.

Pregnancy and Lactation

Pregabalin is FDA Pregnancy Category C (pre-2015 labeling framework); the current label notes that animal studies show fetal harm and that adequate human data are lacking [4]. GHK-Cu has no human pregnancy or lactation data. The combination should be avoided in pregnant or breastfeeding patients.

Older Adults

Older adults (age 65 and above) are more susceptible to pregabalin-related dizziness and falls. A 2016 population-based cohort study published in BMJ (N=8,859 new pregabalin users) found a significantly elevated risk of road traffic accidents and falls in the first weeks of therapy [10]. Adding a poorly characterized peptide to this population without data warrants particular caution.

What the Literature Does and Does Not Support

Available GHK-Cu Human Evidence

Published human clinical trials on GHK-Cu are limited almost entirely to topical dermatology applications. A small randomized controlled trial (N=67) by Leyden et al. Showed GHK-Cu-containing cream improved periorbital rhytides versus vehicle [11]. No randomized controlled trial of systemic GHK-Cu (subcutaneous or intravenous) in humans has been published in a peer-reviewed journal as of mid-2025. The mechanistic data cited throughout this article derive from in vitro fibroblast studies and rodent models, which limits generalizability [1].

Available Pregabalin Interaction Evidence

Pregabalin's interaction profile is well characterized through its NDA submission and post-marketing studies. The FDA label documents specific interactions with oxycodone (additive CNS depression), lorazepam (additive CNS depression), and ethanol (additive CNS depression) [4]. The label found no PK interaction with gabapentin, carbamazepine, valproic acid, lamotrigine, phenytoin, or topiramate [4]. GHK-Cu is not listed because it was not tested and is not an FDA-approved drug.

Dose-Adjustment Guidance

No evidence-based dose adjustment is possible for this combination because no human PK/PD interaction trial exists. The practical guidance is:

• Maintain pregabalin at the lowest effective dose per FDA labeling (starting 150 mg/day for most indications, titrated as tolerated) [4].
• If GHK-Cu is initiated while on stable pregabalin, begin at the lowest available compounded concentration and reassess CNS symptoms at two weeks.
• Do not increase pregabalin dose and start GHK-Cu simultaneously; staggering changes allows attribution of any adverse effect.